An experimental vaccine against the lethal Ebola virus has been administered to humans for the first time in November 2003. If the trial proves successful, then the vaccine will be commercialised by 2006, a decade sooner than the time, it was thought, it would take to develop the inoculation. The potential to use the virus as a bioterrorism weapon is one of the major factors determining the speed at which the vaccine was developed. It can also be used as a preventive tool in countries where the virus is endemic
an experimental vaccine against the lethal Ebola virus has been administered to humans for the first time in November 2003. If the trial proves successful, then the vaccine will be commercialised by 2006, a decade sooner than the time, it was thought, it would take to develop the inoculation. The potential to use the virus as a bioterrorism weapon is one of the major factors determining the speed at which the vaccine was developed. It can also be used as a preventive tool in countries where the virus is endemic.
It is the first of two vaccines being developed by researchers from the us-based National Institutes of Health (nih). During tests on monkeys in 2000, it was found to be 100 per cent effective. The human trial would involve 27 volunteers. Six of them would be given a placebo. The rest will receive three injections during two stages of the treatment. In the first stage, the immune system will be 'primed' by the direct injection of non-infectious genetic material of the virus. The presence of the genetic material will initiate the production of antibodies against the virus on a large-scale.
During the second stage, the immune system's response will be 'boosted' with the help of the two other jabs, which contain the common cold-causing viruses genetically modified to incorporate the genetic material of the Ebola virus. The material is incorporated in the common cold viruses so that it can be replicated when they multiply. If the Ebola virus attacks the person in future, then his/her immune system will have a 'memory' of the virus; this will help in quickly producing the desired immunity. In an unvaccinated person, the production of antibodies would be slower than what is required.
The researchers claim that their vaccine is safe, as it does not contain any infectious material from the virus. However, there is a hitch -- the human body is accustomed to attacks by the common cold virus, and hence it may not produce the antibodies if the virus is injected several times. Two people have been given the vaccine to date. All the subjects will be followed up for one year. The researchers would collect blood samples to measure the type and duration of the immune system's response. The subjects would not be infected by the virus to gauge the effectiveness of the treatment as it is too risky to do so.
|
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.